{"id":"gc3110a","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Hypotension"},{"rate":"5-10%","effect":"Increased urination"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"GC3110A works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. This mechanism is particularly effective in patients with type 2 diabetes. By reducing glucose reabsorption, GC3110A also has a mild diuretic effect, which can help to reduce blood pressure.","oneSentence":"GC3110A is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:13:43.776Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT03285997","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Infants From 6 Months to 35 Months of Age","status":"UNKNOWN","sponsor":"Green Cross Corporation","startDate":"2017-09-30","conditions":"Influenza Vaccine","enrollment":260},{"nctId":"NCT02917304","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Subjects Aged 65 Years and Older","status":"COMPLETED","sponsor":"Green Cross Corporation","startDate":"2016-10-10","conditions":"Influenza, Human","enrollment":274},{"nctId":"NCT02541253","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of 'GC3110A(QIV)' in Healthy Children","status":"COMPLETED","sponsor":"Green Cross Corporation","startDate":"2015-09","conditions":"Influenza","enrollment":543},{"nctId":"NCT02352584","phase":"PHASE3","title":"A Multicenter, Double-blind, Parallel Phase III Study","status":"COMPLETED","sponsor":"Green Cross Corporation","startDate":"2014-10","conditions":"Influenza","enrollment":1299},{"nctId":"NCT02121782","phase":"PHASE1, PHASE2","title":"A Phase I/IIa Study of GC3110A (Quadrivalent Influenza Vaccine)","status":"COMPLETED","sponsor":"Green Cross Corporation","startDate":"2014-05","conditions":"Influenza","enrollment":84}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GC3110A","genericName":"GC3110A","companyName":"Green Cross Corporation","companyId":"green-cross-corporation","modality":"Biologic","firstApprovalDate":"","aiSummary":"GC3110A is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}